Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 27:12:58.
doi: 10.1186/1472-6947-12-58.

A novel differential diagnostic model based on multiple biological parameters for immunoglobulin A nephropathy

Affiliations

A novel differential diagnostic model based on multiple biological parameters for immunoglobulin A nephropathy

Jing Gao et al. BMC Med Inform Decis Mak. .

Abstract

Background: Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis in China. An accurate diagnosis of IgAN is dependent on renal biopsies, and there is lack of non-invasive and practical classification methods for discriminating IgAN from other primary kidney diseases. The objective of this study was to develop a classification model for the auxiliary diagnosis of IgAN using multiparameter analysis with various biological parameters.

Methods: To establish an optimal classification model, 121 cases (58 IgAN vs. 63 non-IgAN) were recruited and statistically analyzed. The model was then validated in another 180 cases.

Results: Of the 57 biological parameters, there were 16 parameters that were significantly different (P < 0.05) between IgAN and non-IgAN. The combination of fibrinogen, serum immunoglobulin A level, and manifestation was found to be significant in predicting IgAN. The validation accuracies of the logistic regression and discriminant analysis models were 77.5 and 77.0%, respectively at a predictive probability cut-off of 0.5, and 81.1 and 79.9%, respectively, at a predictive probability cut-off of 0.40. When the predicted probability of the equation containing the combination of fibrinogen, serum IgA level, and manifestation was more than 0.59, a patient had at least an 85.0% probability of having IgAN. When the predicted probability was lower than 0.26, a patient had at least an 88.5% probability of having non-IgAN. The results of the net reclassification improvement certificated serum Immunoglobulin A and fibrinogen had classification power for discriminating IgAN from non-IgAN.

Conclusions: These models possess potential clinical applications in distinguishing IgAN from other primary kidney diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Respective ROC Curve of sIgA, ALB and Ca between IgAN and non-IgAN. ROC curves for serum immunoglobulin A level (sIgA), ALB (albumin) and Ca (calcium) in immunoglobulin A nephropathy (IgAN) and non-immunoglobulin A nephropathy (non-IgAN) patients. The state variable is IgAN.
Figure 2
Figure 2
Correlation coefficients between two variables of pre-selected variables.
Figure 3
Figure 3
Figure3Area under ROC curve of the predicted probability of IgAN with “FIB + sIgA + Manifestation” combination from logistic regression. Area under the ROC curve for predicting immunoglobulin A nephropathy (IgAN) with the equation derived via logistic regression analysis, which includes the “fibrinogen (FIB) + serum immunoglobulin A level (sIgA) + manifestation” combination. The state variable is IgAN.
Figure 4
Figure 4
Area under ROC curve of the predicted probability of IgAN with “FIB + sIgA + Manifestation” combination from discriminant analysis. Area under the ROC curve for predicting immunoglobulin A nephropathy (IgAN) with the equation derived via discriminant analysis, which includes the “fibrinogen (FIB) + serum immunoglobulin A level (sIgA) + manifestation” combination. The state variable is IgAN.
Figure 5
Figure 5
Misdiagnosis rates of the two models with different cut-offs for the predicted probability.
Figure 6
Figure 6
Decision procedure for the diagnosis of immunoglobulin A (IgA) and non-IgA nephropathy in patients with suspected kidney disease.

Similar articles

Cited by

References

    1. Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol. 2011;22:1785–1794. doi: 10.1681/ASN.2011030221. - DOI - PubMed
    1. Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol. 2009;5:132–142. - PubMed
    1. Bomback AS, Radhakrishnan J. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) Discov Med. 2011;12:91–96. - PubMed
    1. Ponticelli C, Passerini P. The place of cyclosporin in the management of primary nephrotic syndrome. BioDrugs. 1999;12:327–341. doi: 10.2165/00063030-199912050-00002. - DOI - PubMed
    1. Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis. 2010;17:420–427. doi: 10.1053/j.ackd.2010.06.002. - DOI - PubMed

Publication types

LinkOut - more resources